Lu Wang

Dr. Lu Wang

orcid

Research Focus & Metrics

Representative Publications

View All Publications
16 August 2024 in Blood Advances
Verified
Journal Article
Open access
LWLu Wang
Lu Wang
JWJialing Wang
Jialing Wang
JLJihong Li
Jihong Li
TWThomas Walz
Thomas Walz
BCBarry Coller
Barry Coller
Monoclonal antibodies (mAbs) have provided valuable information regarding the structure and function of platelet αIIbβ3. Protein disulfide isomerase (PDI) has been implicated in αIIbβ3 activation and binds to thrombin-activated αIIbβ3. Using human platelets as the immunogen, we identified a new mAb (R21D10) that inhibits the binding of PDI to platelets activated with thrombin receptor–activating peptide (T6). R21D10 also partially inhibited T6-induced fibrinogen and PAC-1 binding to platelets, as well as T6- and adenosine 5'-diphosphate–induced platelet aggregation. Mutual competition experiments showed that R21D10 does not inhibit the binding of mAbs 10E5 (anti-αIIb cap domain) or 7E3 (anti-β3 β-I domain), and immunoblot studies indicated that R21D10 binds to β3. The dissociation of αIIbβ3 by EDTA had a minimal effect on R21D10 binding. Cryogenic electron microscopy of the αIIbβ3-R21D10 Fab complex revealed that R21D10 binds to the β3 integrin-epidermal growth factor 1 (I-EGF1) domain and traps an intermediate conformation of αIIbβ3 with semiextended leg domains. The binding of R21D10 produces a major structural change in the β3 I-EGF2 domain associated with a new interaction between the β3 I-EGF2 and αIIb thigh domains, which may prevent the swing-out motion of the β3 hybrid domain required for high-affinity ligand binding and protect αIIbβ3 from EDTA-induced dissociation. R21D10 partially reversed the ligand binding priming effect of eptifibatide, suggesting that it could convert the swung-out conformation into a semiextended conformation. We concluded that R21D10 inhibits ligand binding to αIIbβ3 via a unique allosteric mechanism, which may or may not be related to its inhibition of PDI binding.

1 May 2026 in Blood Advances
Verified
Journal Article
Open access
LWLu Wang
Lu Wang
JWJialing Wang
Jialing Wang
JLJihong Li
Jihong Li
BCBarry Coller
Barry Coller
Platelet integrin αIIbβ3 plays a pivotal role in hemostasis and thrombosis. Protein disulfide isomerase (PDI) binds to αIIbβ3 and mediates its activation. The binding region(s) on αIIbβ3 for PDI remains to be established. We identified a new anti-αIIbβ3 murine monoclonal antibody, R21C11, that inhibits PDI binding to platelets, ligand binding to αIIbβ3, and platelet aggregation. R21C11 inhibited recombinant PDI binding to platelets activated with the PAR1 thrombin receptor activating peptide SFLLRN (T6). Reciprocally, PDI partially reduced R21C11 binding to platelets. PDI was translocated to the platelet surface after activation and activated platelets showed higher PDI reductase activity. R211C11 decreased both the amount of PDI and the reductase activity. R21C11 partially inhibited both fibrinogen and PAC-1 binding to αIIbβ3 and platelet aggregation induced by ADP and T6. R21C11 bound slowly to unactivated platelets and more rapidly after T6 activation; eptifibatide, which induces the αIIbβ3 extended-open conformation, also increased the speed of R21C11 binding. Activation also increased total R21C11 binding. Cryogenic electron microscopy single-particle analysis of the R21C11 Fab–αIIbβ3 complex revealed that R21C11 binds to the β3 β-tail domain in both nearly bent and semiextended-closed conformations of αIIbβ3. R21C11 Fab clashed with the β3 β-I domain in the fully bent conformation, accounting for the slow binding rate of R21C11. These data are consistent with R21C11 inhibiting PDI binding by steric hindrance and the activation dependence of PDI binding. Taken together, these data suggest that the β-tail domain and/or neighboring area is the binding site for PDI on integrin αIIbβ3.